アブストラクト
| Title | シスプラチン連日投与レジメンにおけるマグネシウム投与の有無による腎機能変動の実態調査 |
|---|---|
| Subtitle | 論文 原著論文 |
| Authors | 橋詰淳哉1, 仮屋洋佑1, 川原和也2, 宮永圭1, 神田紘介1, 室高広3, 中村忠博1, 坂口功一4, 佐々木均1, 兒玉幸修1 |
| Authors (kana) | |
| Organization | 1長崎大学病院薬剤部, 2地域医療機能推進機構諫早総合病院薬剤部, 3長崎国際大学薬学部, 4長崎大学病院耳鼻咽喉科・頭頸部外科 |
| Journal | 日本病院薬剤師会雑誌 |
| Volume | 56 |
| Number | 10 |
| Page | 1168-1174 |
| Year/Month | 2020 / 10 |
| Article | 原著 |
| Publisher | 日本病院薬剤師会 |
| Abstract | シスプラチン(cisplatin: 以下, CDDP)単回投与時のマグネシウム(magnesium: 以下, Mg)投与は腎障害を予防・軽減することが報告されているが, CDDP連日投与時についての報告は見当たらない. 長崎大学病院では頭頸部がんのCDDP連日投与レジメンにおいて, 2017年4月より全例にMg予防投与を行っている. Mg予防投与の有無による腎機能の変動を調査した. 解析対象患者はレジメン変更前群35名, レジメン変更後群32名であった. 1コース中におけるクレアチニンクリアランス(creatinine clearance: 以下, CCr)最低値と基準値との差(以下, ΔCCr)の中央値はレジメン変更前群で12.7, レジメン変更後群で3.1であった. 重回帰分析の結果, レジメン変更はΔCCrに対して有意な負の相関を示した(p=0.012). Mg投与によりCDDP連日投与時の腎障害を予防・軽減できる可能性が示唆された. |
| Practice | 薬学 |
| Keywords | シスプラチン, マグネシウム, 連日投与, 予防投与 |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) N Pabla, Z Dong : Cisplatin nephrotoxicity : mechanisms and renoprotective strategies, Kidney Int, 73, 994-1007(2008).
- 2) T Yoshida, S Niho, M Toda, K Goto, K Yoh, S Umemura, S Matsumoto, H Ohmatsu, Y Ohe : Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity : a retrospective study, Jpn J Clin Oncol, 44, 346-354(2014).
- 3) Y Saito, M Kobayashi, T Yamada, K Kasashi, R Honma, S Takeuchi, Y Shimizu, I Kinoshita, H Dosaka-Akita, K Iseki : Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity, Support Care Cancer, 25, 481-487(2017).
- 4) H Konishi, H Fujiwara, H Itoh, A Shiozaki, T Arita, T Kosuga, R Morimura, S Komatsu, D Ichikawa, K Okamoto, E Otsuji : Influence of magnesium and parathyroid hormone on cisplatin-induced nephrotoxicity in esophageal squamous cell carcinoma, Oncol Lett, 15, 658-664(2018).
- 5) Y Kidera, H Kawakami, T Sakiyama, K Okamoto, K Tanaka, M Takeda, H Kaneda, S Nishina, J Tsurutani, K Fujiwara, M Nomura, Y Yamazoe, Y Chiba, S Nishida, T Tamura, K Nakagawa : Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection, PLoS One[Internet], 2014 Jul 14, 9. doi : 10.1371/journal.pone.0101902.
残りの20件を表示する
- 6) HR Brady, ML Zeidel, BC Kone, G Giebisch, SR Gullans : Differential actions of cisplatin on renal proximal tubule and inner medullary collecting duct cells, J Pharmacol Exp Ther, 265, 1421-1428(1993).
- 7) MS Park, M De Leon, P Devarajan : Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways, J Am Soc Nephrol, 13, 858-865(2002).
- 8) JE Buckley, VL Clark, TJ Meyer, NW Pearlman : Hypomagnesemia after cisplatin combination chemotherapy, Arch Intern Med, 144, 2347-2348(1984).
- 9) C Bokemeyer, CC Berger, MA Kuczyk, HJ Schmoll : Evaluation of long-term toxicity after chemotherapy for testicular cancer, J Clin Oncol, 14, 2923-2932(1996).
- 10) E Hodgkinson, HL Neville-Webbe, RE Coleman : Magnesium depletion in patients receiving cisplatin-based chemotherapy, Clin Oncol, 18, 710-718(2006).
- 11) 山本泰大, 渡辺員支, 松下 宏, 築山郁人, 松浦克彦, 若槻 明 : 子宮頸がんに対するシスプラチン単剤投与による低マグネシウム血症の発現率調査, YAKUGAKU ZASSHI, 137, 79-82(2017).
- 12) A Yonezawa, S Masuda, K Nishihara, I Yano, T Katsura, K Inui : Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2(Slc22a2)in the rat, Biochem Pharmacol, 70, 1823-1831(2005).
- 13) K Yokoo, R Murakami, T Matsuzaki, K Yoshitome, A Hamada, H Saito : Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats, Clin Exp Nephrol, 13, 578-584(2009).
- 14) Y Saito, K Okamoto, M Kobayashi, K Narumi, T Yamada, K Iseki : Magnesium attenuates cisplatin-induced nephrotoxicity by regulating the expression of renal transporters, Eur J Pharmacol, 811, 191-198(2017).
- 15) AG Casanova, MT Hernandez-Sanchez, FJ Lopez-Hernandez, C Martinez-Salgado, M Prieto, L Vicente-Vicente, AI Morales : Systematic review and meta-analysis of the efficacy of clinically tested protectants of cisplatin nephrotoxicity, Eur J Clin Pharmacol, 76, 23-33(2020).
- 16) DJ Crona, A Faso, TF Nishijima, KA McGraw, MD Galsky, MI Milowsky : A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity, Oncologist, 22, 609-619(2017).
- 17) T Oka, T Kimura, T Suzumura, N Yoshimoto, T Nakai, N Yamamoto, K Matsuura, S Mitsuoka, N Yoshimura, S Kudoh, K Hirata : Magnesium Supplementation and High Volume Hydration Reduce the Renal Toxicity Caused by Cisplatin-Based Chemotherapy in Patients With Lung Cancer : A Toxicity Study, BMC Pharmacol Toxicol[Internet], 2014 Dec 4, 15. doi : 10. 1186/2050-6511-15-70.
- 18) D Rades, D Seidl, S Janssen, A Bajrovic, SG Hakim, B Wollenberg, K Karner, P Strojan, SE Schild : Chemoradiation of locally advanced squamous cell carcinoma of the head-and-neck(LASCCHN): Is 20mg/m2 cisplatin on five days every four weeks an alternative to 100mg/m2 cisplatin every three weeks?, Oral Oncol, 59, 67-72(2016).
- 19) IB Afanas'ev, TB Suslova, ZP Cheremisina, NE Abramova, LG Korkina : Study of antioxidant properties of metal aspartates, Analyst, 120, 859-862(1995).
- 20) MH Solanki, PK Chatterjee, M Gupta, X Xue, A Plagov, MH Metz, R Mintz, PC Singhal, CN Metz : Magnesium protects against cisplatin-induced acute kidney injury by regulating platinum accumulation, Am J Physiol Renal Physiol, 307, F369-F384(2014).
- 21) 中本恵理, 川上和宜, 今田洋司, 式部さあ里, 杉田一男, 篠崎英司, 末永光邦, 松阪 諭, 水沼信之, 濱 敏弘 : Cetuximab投与後に生じる低マグネシウム血症の発現頻度と発現時期の調査とその対策, 医療薬学, 37, 403-409(2011).
- 22) 中村忠博, 松永典子, 樋口則英, 北原隆志, 佐々木均 : 酸化マグネシウム製剤の腎機能低下患者における血清マグネシウム値への影響, 日本腎臓病薬物療法学会誌, 2, 3-9(2013).
- 23) T Mizuno, K Ishikawa, W Sato, T Koike, M Kushida, Y Miyagawa, K Yamada, S Hirata, E Imai, Y Noda : The Risk Factors of Severe Acute Kidney Injury Induced by Cisplatin, Oncology, 85, 364-369(2013).
- 24) H Horinouchi, K Kubota, H Itani, TK Taniyama, S Nakamichi, H Wakui, S Kanda, H Nokihara, N Yamamoto, I Sekine, T Tamura : Short hydration in chemotherapy containing cisplatin(>-75mg/m2)for patients with lung cancer : a prospective study, Jpn J Clin Oncol, 43, 1105-1109(2013).
- 25) H Horinouchi, K Kubota, A Miyanaga, S Nakamichi, M Seike, A Gemma, Y Yamane, F Kurimoto, H Sakai, S Kanda, Y Fujiwara, H Nokihara, N Yamamoto, T Tamura, Y Ohe : Oral rehydration solution(OS-1) as a substitute of intravenous hydration after cisplatin administration in patients with lung cancer : a prospective multicenter trial, ESMO Open[Internet], 2018 Jan 29, 3. Doi : 10. 1136/esmoopen-2017-000288.
